Sotatercept for the Treatment of Pulmonary Arterial Hypertension

2021544 citationsJournal Articlebronze Open Access

Authors

Marc Humbert · Inserm

Vallerie V. McLaughlin · Inserm

J. Simon R. Gibbs · Imperial College Healthcare NHS Trust

Mardi Gomberg‐Maitland · Inserm

Marius M. Hoeper · Inserm

Ioana R. Preston · Tufts Medical Center

Rogério Souza · Inserm

Abstract

Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. (Funded by Acceleron Pharma; PULSAR ClinicalTrials.gov number, NCT03496207.).

Topics & Keywords

Pulmonary Hypertension Research and Treatments Vascular Anomalies and Treatments Liver Disease and Transplantation

UN Sustainable Development Goals

No poverty

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 13, pp. 1204-1215

DOI: 10.1056/nejmoa2024277

Field-Weighted Citation Impact: 53.37